CPT1A and neoplasm: To verify the anti-tumor effect of sh-RACGAP1 in vivo, we established xenograft tumor models by subcutaneously injecting MDA-MB-231 cells, and MDA-MB-231 cells transfected with NC, sh-RACGAP1 and sh-RACGAP1 + oe-CPT1A, respectively.